Participate in the Essential Tremor M21-471
Clinical Trial Today

Interested in participating in an essential tremor Clinical Trial?

Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor 

Study Description 

Brief Summary: 

Upper limb essential tremor (UL ET) is a movement disorder characterized by postural and/or kinetic tremor. It can cause difficulty with everyday tasks such as writing, pouring, and eating, and patients also experience associated social embarrassment. This study will assess how safe and effective BOTOX is in treating UL ET. Adverse events and change in disease activity will be evaluated. 

BOTOX is an investigational drug being developed for the treatment of UL ET. Participants are randomly assigned to 1 of the 4 groups, called treatment arms. Each group receives different treatment. There is 1 in 2 chance that participants will be assigned to placebo. Around 174 participants, aged 18 to 80 years with UL ET will be enrolled in approximately 40 sites in North America. 

Participants will receive BOTOX or placebo injections in Cycle 1 and Cycle 2. In Cycle 3, participants will receive unilateral or bilateral BOTOX injections. Each cycle is 12 weeks. 

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires. 

If you would like to hear about more about our current or upcoming neurological clinical trials in Montreal please sign up below.








Eligibility Criteria 

  • Ages Eligible for Study:  18 Years to 80 Years   (Adult, Older Adult) 

  • Sexes Eligible for Study:  All 

  • Accepts Healthy Volunteers:  No 

Inclusion Criteria: 

Diagnosis of essential tremor in accordance with modified Tremor Investigation Group (TRIG) criteria as described in the protocol. 

  • TREDS-Revised Scale (1-4 scale, whole numbers) unilateral score of >= 3 for the Tremor Disability Scale (TREDS) on any of the 7 unilateral items; no more than a single item score of 1 among the 7 unilateral items in the dominant limb. 

  • TETRAS activities of daily living (ADL) (recorded on a 0-4 scale, whole numbers) minimum score of >= 3 on any of the 5 unilateral items; no more than a single item score of <=1 among the 5 unilateral items in the dominant limb. 

  • At least one of the following criteria must also be met: 

  • TETRAS UL score (0-4 scale, with 0.5 increments) of > 2 in the dominant limb on at least one of the 3 maneuvers OR TETRAS Archimedes spiral task score (0-4 scale, with 0.5 increments) of > 2 in the dominant limb 

Exclusion Criteria: 

  • Any uncontrolled clinically significant medical condition other than the one under study. 

  • Any medical condition that may put the participant at increased risk with exposure to BOTOX Purified Neurotoxin Complex. 

“If we’re not in the beginning for rare disease, we may simply be too late for our patients to get the benefit of these new therapies.”

-Angela Genge

  • Our mission

    To improve patient health and well-being by conducting cutting-edge clinical research. We strive to foster a culture of innovation, collaboration, and excellence in all aspects of our research, and to contribute to the global effort to improve healthcare for all.

  • Our vision

    To be a leading force in advancing medical knowledge and improving patient care through innovative and ethical clinical research

  • Our future

    Genge Partners will continue to be at the forefront of clinical research, utilizing the latest technologies and methodologies to bring new treatments and therapies to patients in need. Our commitment to patient safety, scientific rigor, and ethical conduct will remain steadfast, as we work to improve healthcare for all and make a lasting impact on the field of medicine.

Our facilities:

Genge Partners @ Glen
5100 Boul. de Maisonneuve Ouest, 6th floor
Montreal, QC H4A 3TA

Genge Partners @ Pointe Claire
955 Boul Saint-Jean, Suite 212
Pointe-Claire, QC H9R 5K3

 

© 2022 Genge Partners Inc. All rights reserved | Confidentiality policy